Accelerating clinical studies in retina: What Ora Clinical is doing to help

Author(s):

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

Video Player is loading.

Current Time 0:00

Duration 8:48

Loaded: 0%

Stream Type LIVE

Remaining Time 8:48

David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.

Related Videos

NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula

Part 3: Biggest innovations in ophthalmology in 50 years

(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025

Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care

Part 2: Biggest innovations in ophthalmology in 50 years

Part 1: Biggest innovations in ophthalmology in 50 years

World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD

$(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD$

The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD

AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD

AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH

Anat Loewenstein comments on the recent FDA approval of revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2 treatment